Any current/future new fundraising through debt or equity?

The company has taken an enabling resolution to raise funds through equity or debt to stay prepared for any growth opportunities. No concrete proposals for inorganic acquisitions or fundraising are currently on the table. The management is evaluating options, particularly for acquisitions in segments like defence, aerospace, and railways. Any future fundraising will be targeted towards long-term business growth. Current gross debt stands at INR576 crores, mainly working capital debt (INR490 crores). The company plans to be free cash flow positive in FY25, with a focus on optimizing working cap

Any current/future capex/capital investment/strategic investment?

Completed organic capex of ~INR333-340 crores in FY24 across multiple projects (Manesar 3, Chennai, Hosur, Pune, Bawal). Average asset utilization as of March 2024 is ~65-70%, indicating capacity to grow without immediate new capex. Planned capex for FY25 is about INR150 crores, mainly for balancing equipment and aimed at FY26 revenue targets. No concrete inorganic acquisition proposals currently, but management is evaluating opportunities in defense, aerospace, and railways to expand product offerings. Enabling resolution passed to raise funds for potential organic or inorganic growth opportu

Future growth expectations in sales/revenue/volumes?

Management targets maintaining a high growth trajectory of 40-45% year-on-year revenue growth in the coming years (Page 23). Exports are expected to continue growing at about 20-30% annually, potentially higher, driven by increased presence in Western Europe and established export base (Pages 22, 23). Healthcare (MedTech) business projected to grow significantly, around 25-30% in the near term, contributing increasingly to revenue and profitability (Pages 12-13). Consumer business expected to stabilize between 37-40% of revenues in FY25, with a management goal to reduce this mix to 30-35% over

Future growth expectations in earnings/operating earnings/profits/EPS?

Management targets a **40-45% CAGR growth** in revenue for FY25, continuing a strong growth trajectory seen over the past 3 years (54% YoY in FY24). **Exports** are expected to grow around **20-30%** in coming years, maintaining their forte with a $100 million export base. Operating EBITDA margin guidance is maintained at **7% for FY25**, slightly improved from 6.8% in FY24, with quarterly variations possible. Profitability expected to stabilize with **stable margins** despite rapid growth, focusing on operational efficiencies and cost control. MedTech vertical is poised to be a signif

Current/ Expected Orderbook/ Pending Orders?

Current order book visibility is approximately INR 4,500 crores. Segment-wise breakup: - Consumer business: ~40% of order book - Industrial business: 20% - 25% - Automotive sector: 20% - 22% - Healthcare: 5% - 7% - Balance from IT and railways Export orders constitute around 22% - 25% of the total order book. Order book remained flat sequentially (around INR 4,500 crores) due to higher execution in Q4, not due to demand slowdown. Railway orders visibility: expected INR 45-50 crores in the current year, with potential to reach INR 25-30 crores revenue in the second h

IN US

Sale is live|00:00:00left today

Syrma SGS Technology LtdQ1 FY24Industrial Manufacturing

Syrma SGS Technology Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,385P/E: 60.9Market Cap: ₹19.5K CrSector: Industrial Manufacturing

Management growth scorecard

Revenue

Category 1

Margin

Category 3

Fundraise

Yes

Order

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 1

→Management targets maintaining a high growth trajectory of 40-45% year-on-year revenue growth in the coming years (Page 23).
→Exports are expected to continue growing at about 20-30% annually, potentially higher, driven by increased presence in Western Europe and established export base (Pages 22, 23).
→Healthcare (MedTech) business projected to grow significantly, around 25-30% in the near term, contributing increasingly to revenue and profitability (Pages 12-13).
→Consumer business expected to stabilize between 37-40% of revenues in FY25, with a management goal to reduce this mix to 30-35% over the longer term, shifting focus more towards industrial and automotive segments (Pages 19, 12).
→Capacity expansion and operational efficiencies are planned to support this growth, with commissioning of new plants and facilities in Pune and Germany slated for FY25 (Pages 4, 22).
→ODM design subsidiary expected to start contributing revenues from FY25 onwards, growing steadily thereafter (Page 21).

Margin guidance

Category 3

→Management targets a **40-45% CAGR growth** in revenue for FY25, continuing a strong growth trajectory seen over the past 3 years (54% YoY in FY24).
→**Exports** are expected to grow around **20-30%** in coming years, maintaining their forte with a $100 million export base.
→Operating EBITDA margin guidance is maintained at **7% for FY25**, slightly improved from 6.8% in FY24, with quarterly variations possible.
→Profitability expected to stabilize with **stable margins** despite rapid growth, focusing on operational efficiencies and cost control.
→MedTech vertical is poised to be a significant contributor to bottom line with expected growth of **25-30%** and higher in future years.
→Company plans positive **operating cash flow (OCF) in FY25**, with focus on working capital improvement.
→No inorganic growth proposals finalized yet, but management is open to strategic acquisitions in defense, aerospace, and railways sectors.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→The company has taken an enabling resolution to raise funds through equity or debt to stay prepared for any growth opportunities.
→No concrete proposals for inorganic acquisitions or fundraising are currently on the table.
→The management is evaluating options, particularly for acquisitions in segments like defence, aerospace, and railways.
→Any future fundraising will be targeted towards long-term business growth.
→Current gross debt stands at INR576 crores, mainly working capital debt (INR490 crores).
→The company plans to be free cash flow positive in FY25, with a focus on optimizing working capital to reduce debt reliance.
→No immediate plans for debt or equity issuance have been announced; decisions will be communicated once concrete proposals emerge.

Order book

→Current order book visibility is approximately INR 4,500 crores.
→Segment-wise breakup:
→ - Consumer business: ~40% of order book
→ - Industrial business: 20% - 25%
→ - Automotive sector: 20% - 22%
→ - Healthcare: 5% - 7%
→ - Balance from IT and railways
→Export orders constitute around 22% - 25% of the total order book.
→Order book remained flat sequentially (around INR 4,500 crores) due to higher execution in Q4, not due to demand slowdown.
→Railway orders visibility: expected INR 45-50 crores in the current year, with potential to reach INR 25-30 crores revenue in the second half of the year post RDSO approval.
→Consumer business is expected to constitute 37%-40% of revenues in FY25, included in order book projections.

Capex plans

Yes

→Completed organic capex of ~INR333-340 crores in FY24 across multiple projects (Manesar 3, Chennai, Hosur, Pune, Bawal).
→Average asset utilization as of March 2024 is ~65-70%, indicating capacity to grow without immediate new capex.
→Planned capex for FY25 is about INR150 crores, mainly for balancing equipment and aimed at FY26 revenue targets.
→No concrete inorganic acquisition proposals currently, but management is evaluating opportunities in defense, aerospace, and railways to expand product offerings.
→Enabling resolution passed to raise funds for potential organic or inorganic growth opportunities; specific uses to be decided upon firm proposals.
→Expansion of 40,000 sq. ft. facility in Stuttgart, Germany planned (fit-out by Q2/Q3 FY25) primarily for integration, with potential future manufacturing.
→Commissioning design center in Pune focused on MedTech ODM business expected by Q2 FY25.
→Target to optimize working capital and improve operating cash flow alongside these investments.

How does Syrma SGS Technology Ltd rank vs peers in Industrial Manufacturing?

Pro feature

1Syrma SGS Technology Ltd

Rev 1Mar 3

See full Industrial Manufacturing sector rankings

Want more stocks like Syrma SGS Technology Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio